Advancing injectable therapy in adults with T2D: Findings from the SoliMix trial

18:30 – 18:35

Symposium introduction

Julio Rosenstock (USA)

18:35 – 18:55

Glycemic goals and overcoming barriers: Unmet needs for people with T2D

Francesco Giorgino (ITA)
Julio Rosenstock (USA)
18:55 – 19:15

Advancing basal insulin therapy in the SoliMix trial: What does it mean for adults with T2D?

Rory McCrimmon (UK)
Katherine Whitmire (USA)

19:15 – 19:25

Panel discussion

All Speakers

19:25 – 19:30

Summary and close

Julio Rosenstock (USA)

The SoliMix trial was the first randomized controlled trial to directly compare the efficacy and safety of a fixed-ratio combination of basal insulin and GLP-1 RA, iGlarLixi, with a premix insulin analog, biphasic insulin aspart 30 (30% insulin aspart and 70% insulin aspart protamine) (BIAsp 30), in people with Type 2 diabetes uncontrolled on basal insulin plus one or two oral antihyperglycemic drugs.